Free Trial

Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Director Sells 675 Shares of Stock

USANA Health Sciences logo with Medical background

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert A. Fuller sold 675 shares of the business's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gilbert A. Fuller also recently made the following trade(s):

  • On Wednesday, August 7th, Gilbert A. Fuller sold 674 shares of USANA Health Sciences stock. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06.

USANA Health Sciences Trading Up 2.9 %

NYSE USNA traded up $1.11 during trading on Tuesday, reaching $39.02. The company's stock had a trading volume of 52,053 shares, compared to its average volume of 80,753. The firm has a market capitalization of $743.33 million, a price-to-earnings ratio of 13.40, a price-to-earnings-growth ratio of 1.27 and a beta of 0.89. USANA Health Sciences, Inc. has a 12 month low of $34.15 and a 12 month high of $54.81. The firm has a 50 day moving average price of $37.56 and a 200 day moving average price of $42.12.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. During the same quarter last year, the business posted $0.59 EPS. On average, equities analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on USNA shares. DA Davidson lowered their target price on shares of USANA Health Sciences from $38.00 to $35.00 and set a "neutral" rating on the stock in a report on Wednesday, October 23rd. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, July 24th.

Read Our Latest Research Report on USANA Health Sciences

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its position in shares of USANA Health Sciences by 18.1% during the 1st quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company's stock valued at $1,883,000 after purchasing an additional 5,952 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in USANA Health Sciences by 22.7% during the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company's stock worth $409,000 after purchasing an additional 1,560 shares during the last quarter. BOKF NA boosted its stake in shares of USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company's stock worth $133,000 after buying an additional 2,031 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in USANA Health Sciences by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company's stock valued at $284,000 after buying an additional 494 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in USANA Health Sciences by 2.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 111,492 shares of the company's stock valued at $5,407,000 after acquiring an additional 2,820 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.

About USANA Health Sciences

(Get Free Report)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

Featured Articles

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ This company will win the AI race (From Porter & Company) (Ad)

Should you invest $1,000 in USANA Health Sciences right now?

Before you consider USANA Health Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.

While USANA Health Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?

NVIDIA's Q3 earnings exceeded expectations with 95% revenue growth and 111% EPS growth. Could $200+ be the next target for NVIDIA stock in 2025?

Related Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
How to Profit from NVIDIA’s Earnings: Short-Term Trading Guide
NVIDIA Nears All-Time Highs: How High Can This AI Leader Climb?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines